News Channels

18 Feb 2021 vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
18 Feb 2021 Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
18 Feb 2021 Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
17 Feb 2021 Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)
17 Feb 2021 Altimmune Announces FDA Clearance of AdCOVID™ IND Application
17 Feb 2021 Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
17 Feb 2021 Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
17 Feb 2021 Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
17 Feb 2021 Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
17 Feb 2021 Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders
17 Feb 2021 GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
17 Feb 2021 Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
17 Feb 2021 IDMC has concluded that OlympiA trial of Lynparza crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis
17 Feb 2021 Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
17 Feb 2021 Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
17 Feb 2021 FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
17 Feb 2021 Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora® Cream for treatment of plaque psoriasis
16 Feb 2021 Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™
16 Feb 2021 ReAlta Life Sciences Doses First Subject in Phase 1 Healthy Volunteers Study of RLS-0071
16 Feb 2021 Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up